Project Grant R01EY038055
- Federal Project Grant Award Summary The University of Rochester received a $415,875 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective July 1, 2026 through June 30, 2028. This R21 exploratory grant funds research to develop and validate novel methodologies for targeting and silencing layer-specific frontal feedback pathways in the primate brain, with particular focus on feedback circuits between the frontal eye field (FEF) and...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded a $896,500 Project Grant to The Research Foundation For The State University of New York (operating as Upstate Medical Center) under the Vision Research program (CFDA 93.867), effective September 1, 2025 through August 31, 2027. The research project, titled "YKI-MITF-ECM Regulation of Eye Progenitor Epithelium Morphology," investigates the molecular mechanisms governing eye development and congenital eye...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded $896,500 under the Vision Research program (CFDA 93.867) to The Research Foundation For The State University of New York, operating as Upstate Medical Center, for a project grant commencing September 1, 2025, and concluding August 31, 2027. The award funds research to characterize the transcriptional dynamics and nuclear mobility of the CRX (cone-rod homeobox) homeodomain transcription factor in photoreceptor cells. The...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded a $701,576 Project Grant to the University of California, San Diego, effective July 1, 2026, through April 30, 2030, under the Vision Research program (CFDA 93.867). The award funds research to explore endogenous retinal ganglion cell (RGC) repair mechanisms following injury using engineered human pluripotent stem cell (PSC)-derived three-dimensional retinal organoids as a model system. The research addresses the...
- Federal Cooperative Agreement Award Summary The University of Rochester received $744,451 under a Cooperative Agreement awarded on March 17, 2026, by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) to develop small molecule Proteolysis-Targeting Chimeras (PROTACs) targeting secretory phospholipase A2-IIA (sPLA2-IIA) for the treatment of age-related macular degeneration (AMD) and related macular dystrophies (MDs). The research deliverables include the design,...
- Federal Project Grant Award Summary The University of Rochester received a $678,201 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) to develop a novel antimicrobial drug combination for treating bacterial keratitis (BK), a corneal infection responsible for over 2 million cases of blindness annually. The award, effective May 1, 2026 through April 30, 2028, supports the advancement of a topical ophthalmic antibiotic formulation combining...
- Federal Project Grant Award Summary New York University School of Medicine received $546,439 in federal funding from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) for a project grant awarded April 15, 2026, with an expected completion date of March 31, 2030. The award funds research to develop corneal stromal keratocyte modeling using human cornea organoids (HCOs) derived from induced pluripotent stem cells (iPSCs). The project addresses critical unmet clinical...
- Federal Grant Award Summary Funding Agency: National Eye Institute (NEI), National Institutes of Health Federal Grant Program: Vision Research (CFDA 93.867) Award Amount: $100,228.00 Award Date: December 1, 2026 Performance Period: December 1, 2026 – April 29, 2029 Awardee: The Trustees of Columbia University in the City of New York Columbia University is conducting preclinical research to develop and validate an autologous stem cell transplantation therapy for autosomal dominant retinal...
- Federal Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded a $682,679 Project Grant to The Johns Hopkins University effective July 1, 2026, through January 31, 2030. This research initiative focuses on identifying drivers of retinal ganglion cell (RGC) differentiation from endogenous stem cells—a critical area given that RGCs are the sole neurons capable of relaying visual information from the retina to the brain, and their loss can...
- Federal Project Grant Award Summary The University of Rochester received a $243,672 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded May 1, 2026, with completion targeted for August 31, 2028. The research project investigates the spatial and temporal dynamics of neural interactions underlying attention-related enhancement and suppression of visual processing. The study addresses how visuospatial attention filters incoming sensory...
Summary The University of Rochester received a $684,914 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective July 1, 2026, through March 31, 2030. The award funds development of human induced pluripotent stem cell (hiPSC)-derived retinal tissue models to address the critical shortage of physiologically relevant human retina cell systems for disease modeling and therapeutic research. Retinal diseases account for over 54% of blindness in the United States, yet most mechanistic studies rely on animal models with limited translational applicability to human disease pathways. This project will deliver two primary products: (1) a microphysiological model of comprehensive hiPSC-derived retina that replicates the three-dimensional spherical architecture of the human retina in vivo for disease modeling and drug testing applications, and (2) a planar hiPSC-photoreceptor-retinal pigment epithelium (RPE) tissue construct designed for cell-based therapeutic applications targeting photoreceptor and RPE degeneration. The research integrates human induced pluripotent stem cells, engineered extracellular matrix, microbubble arrays, and microfluidics technology to create translational tools that bridge the gap between basic research and clinical applications for retinal degenerative diseases.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $684.9k | 6/30/26 |